Conditions: Pulmonary Arterial Hypertension
Keywords: Open-label study
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 1192
Healthy volunteers: no

Brief summary:
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.

Detailed description:
Open-label extension

Arms:
arm 1: Sitaxsentan

Interventions: intervention 1: Sitaxsentan
Intervention descriptions: intervention 1: Sitaxsentan 100 mg tablets once daily

Protocol document: